Phase I and pharmacokinetic study of IV vinflunine in cancer patients with liver dysfunction
Vinflunine is a novel tubulin-targeted agent that is currently indicated as a monotherapy in
bladder cancer patients. The recommended dose of 320 mg/m 2 is given as an intravenous …
bladder cancer patients. The recommended dose of 320 mg/m 2 is given as an intravenous …
[引用][C] Phase I and pharmacokinetic study of IV vinflunine in cancer patients with liver dysfunction
JP DELORD, A RAVAUD, J BENNOUNA… - Investigational new …, 2013 - pascal-francis.inist.fr
Phase I and pharmacokinetic study of IV vinflunine in cancer patients with liver dysfunction
CNRS Inist Pascal-Francis CNRS Pascal and Francis Bibliographic Databases Simple …
CNRS Inist Pascal-Francis CNRS Pascal and Francis Bibliographic Databases Simple …
Phase I and pharmacokinetic study of IV vinflunine in cancer patients with liver dysfunction
JP Delord, A Ravaud, J Bennouna… - Investigational New …, 2013 - search.proquest.com
Vinflunine is a novel tubulin-targeted agent that is currently indicated as a monotherapy in
bladder cancer patients. The recommended dose of 320Â mg/m^ sup 2^ is given as an …
bladder cancer patients. The recommended dose of 320Â mg/m^ sup 2^ is given as an …
Phase I and pharmacokinetic study of IV vinflunine in cancer patients with liver dysfunction
JP Delord, A Ravaud, J Bennouna… - Investigational …, 2013 - pubmed.ncbi.nlm.nih.gov
Vinflunine is a novel tubulin-targeted agent that is currently indicated as a monotherapy in
bladder cancer patients. The recommended dose of 320 mg/m (2) is given as an intravenous …
bladder cancer patients. The recommended dose of 320 mg/m (2) is given as an intravenous …
Phase I and pharmacokinetic study of IV vinflunine in cancer patients with liver dysfunction
JP Delord, A Ravaud, J Bennouna, P Fumoleau… - Investigational New …, 2013 - infona.pl
Vinflunine is a novel tubulin-targeted agent that is currently indicated as a monotherapy in
bladder cancer patients. The recommended dose of 320 mg/m2 is given as an intravenous …
bladder cancer patients. The recommended dose of 320 mg/m2 is given as an intravenous …
Phase I and pharmacokinetic study of IV vinflunine in cancer patients with liver dysfunction.
JP Delord, A Ravaud, J Bennouna… - Investigational new …, 2012 - europepmc.org
Vinflunine is a novel tubulin-targeted agent that is currently indicated as a monotherapy in
bladder cancer patients. The recommended dose of 320 mg/m (2) is given as an intravenous …
bladder cancer patients. The recommended dose of 320 mg/m (2) is given as an intravenous …